The state of Texas currently has 34 active clinical trials seeking participants for Asthma research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
NCT03953300
Recruiting
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication. Patients who complete treatment will enter 4 weeks follow-up period.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
04/25/2024
Locations: Research Site, Galveston, Texas +1 locations
Conditions: Asthma
Register for Updates
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
NCT04718389
Recruiting
This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all participants will continue their non-biologic Baseline standard of care (SoC) asthma treatment.
Gender:
All
Ages:
12 years and above
Trial Updated:
04/25/2024
Locations: GSK Investigational Site, Amarillo, Texas +16 locations
Conditions: Asthma
Register for Updates
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
NCT06020014
Recruiting
This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontrolled moderate-to-severe asthma.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/25/2024
Locations: Research Site, Boerne, Texas +2 locations
Conditions: Asthma
Register for Updates
Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma
NCT05398263
Recruiting
A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 28-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/22/2024
Locations: Research Site, El Paso, Texas +1 locations
Conditions: Asthma
Register for Updates
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)
NCT06196879
Recruiting
The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such as lung function and asthma control, and the safety and tolerability of verekitug (UPB-101) compared to placebo.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/22/2024
Locations: Alina Clinical Trials, LLC, Dallas, Texas +5 locations
Conditions: Severe Asthma
Register for Updates
Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old
NCT06290102
Recruiting
The primary objectives of this study are: To determine the pharmacokinetic (PK) profile of fluticasone propionate (Fp) and albuterol sulfate (ABS), delivered in combination, from a single dose of TEV-56248 (Fp and ABS multidose dry powder inhaler with e-module [Fp/ABS eMDPI]) in participants with asthma To compare the PK profiles of Fp for 2 different dose strengths of TEV-56248 to that of fluticasone propionate multidose dry powder inhaler (Fp MDPI) To compare the PK profiles of ABS between th... Read More
Gender:
All
Ages:
Between 4 years and 11 years
Trial Updated:
04/22/2024
Locations: Teva Investigational Site 12001, Boerne, Texas
Conditions: Asthma
Register for Updates
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589
Recruiting
To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids.
Gender:
All
Ages:
Between 5 years and 11 years
Trial Updated:
04/19/2024
Locations: Research Site, Coppell, Texas +2 locations
Conditions: Asthma
Register for Updates
EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
NCT04998604
Recruiting
Primary Objective -To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smell Secondary Objectives To evaluate the efficacy of dupilumab in improving CRSwNP symptoms at Week 24 compared to omalizumab To evaluate the efficacy of dupilumab in improving lung function at Week 24 compared to omalizumab To evaluate the efficacy of dupilumab in improving CRSwNP total symptom score (TSS) at Week 24 compared to omalizumab To evaluate the effect... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: The University Of Texas Health Science Center At Houston Site Number : 8400019, Houston, Texas
Conditions: Chronic Rhinosinusitis With Nasal Polyps, Asthma
Register for Updates
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
NCT05851443
Recruiting
The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/18/2024
Locations: Howland Allergy and Asthma Pllc Dba Orion Clinical Research, Austin, Texas +2 locations
Conditions: Moderate to Severe Asthma
Register for Updates
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
NCT06052267
Recruiting
The primary objective of the study is to demonstrate the efficacy of high dose and low dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic module multidose dry powder inhaler (eMDPI) compared to ABS eMDPI in decreasing severe clinical asthma exacerbation (CAEs). Secondary Objectives: To evaluate the efficacy of Fp/ABS compared to ABS and the effect on systemic corticosteroid (SCS) exposure To evaluate the safety and tolerability of Fp/A BS The duration for each part... Read More
Gender:
All
Ages:
4 years and above
Trial Updated:
04/16/2024
Locations: Teva Investigational Site 15641, Boerne, Texas +17 locations
Conditions: Asthma
Register for Updates
A Culturally Tailored Scalable Asthma Intervention for Hispanic Children (Asthma Guardian)
NCT05892302
Recruiting
This is a two-arm, parallel design, randomized, controlled pilot trial comparing access to Asma Guardián, a culturally tailored multi-component app-based asthma intervention for Hispanic/Latinx school age children with asthma, to usual care.
Gender:
All
Ages:
Between 5 years and 12 years
Trial Updated:
04/15/2024
Locations: University of Texas at Austin, Austin, Texas
Conditions: Asthma in Children
Register for Updates
Dose Ranging Study of SAR443765 Compared With Placebo-control in Adult Participants With Moderate to Severe Asthma
NCT06102005
Recruiting
This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with SC SAR443765 in adult participants aged 18 to 80 years, (inclusive) with moderate to severe asthma.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/11/2024
Locations: TTS Research Site Number : 8400010, Boerne, Texas
Conditions: Asthma
Register for Updates